This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Why Depo-Provera?What to expectSupport & Resources

Support & Resources

VideosMaterials

Depo-Provera® (medroxyprogesterone acetate) Prescribing Information.  Adverse event reporting information can be found at the bottom of the page.

Why Depo-Provera®?

Depo-Provera is one long acting reversible contraception (LARC) to consider, whatever her lifestyle – on-the-go, between children, pregnancy scare, forgetful, change in relationship. 

Facts to consider
  • Available for over 30 years1

  • Administered every 12 weeks2*† – with a text reminder service (see below for details)

  • Estimated 94% effective with typical use and estimated 99.8% effective with perfect use during the first year of treatment if used consistently and correctly3
  • Intramuscular administration with no specialised training required for healthcare professionals2
  • £6.01 for 12 weeks’ cover
Staying on track with Depo-Provera

Your patients can set a reminder, helping them to remember to book an appointment for their next injection to be given on time.

How to register for the Depo-Provera text reminder service

Text DEPO and the date the injection was given to 83311 in this format DD.MM (e.g. DEPO 31.07).
Three weeks before the next injection is due a reminder text will be sent.  After each injection, your patient will need to re-register for the service.

Contraindications

There are a few contraindications to be aware of with Depo-Provera:

  • Hypersensitivity to medroxyprogesterone acetate or to any of excipients listed in section 6.1 of the Summary of Product Characteristics

  • Depo-Provera should not be used during pregnancy, either for diagnosis or therapy.

  • Hypersensitivity to medroxyprogesterone acetate or to any of excipients listed in section 6.1 of the Summary of Product Characteristics

  • Depo-Provera should not be used during pregnancy, either for diagnosis or therapy.

To read the full special warnings and precautions for use for Depo-Provera and see a full list of adverse events, refer to the Summary of Product Characteristics. The benefits of contraceptive options and their risks must be evaluated individually for each woman. If any of the conditions/risk factors mentioned is present, the benefits of Depo-Provera use should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start using it. In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician. The physician should then decide on whether Depo-Provera use should be discontinued.

*Providing the first injection is given during the first five days of a normal menstrual cycle and subsequent injections are given no later than twelve weeks and five days after the previous injection.
Depo-Provera does not protect against sexually transmitted infections (STIs).
Based on cost of one syringe, does not include cost of clinical appointment.
Please refer to Depo-Provera® (medroxyprogesterone acetate) Prescribing Information.

References

Pfizer Data on File, 2013.Depo-Provera Summary of Product Characteristics.Trussell J. Contraceptive failure in the United States. Contraception 2011;(83):397-404.
PP-DEP-GBR-0065. January 2023
Order materials Click hereLoading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​